Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Withdrawn

• Conditions: Thyroid Cancer

• Registration Number: NCT00373711
• Lead Sponsor: Stanford University

Brief Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Detailed Description

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Study Timeline

• Study First Submitted: 2006-09-06
• Study First Submitted QC: 2006-09-06
• Study First Posted: 2006-09-08
• Study Start: 2007-05
• Status Verified: 2011-04
• Last Update Submitted: 2022-06-16
• Last Update Posted: 2022-06-21

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patient at Nuclear Medicine clinic at Stanford University Medical Center

• Treated thyroid cancer.
• Detectable levels of Tg.
• Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
• Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
• Patients older than 18-year-old.
• Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
• Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.

Exclusion Criteria

• Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.

• Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
• Pregnant women.
• Healthy volunteers.
• Patients participating in other research studies.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified